Data / Form D filings / Encentrio Therapeutics, Inc.
Encentrio Therapeutics, Inc.: Form D filing
Encentrio Therapeutics, Inc., a biotechnology company in San Francisco, CA, filed a Form D with the SEC in 2023. The latest, on April 3, 2023, reports $400,000 sold of a $400,000 offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1800 OWENS ST., San Francisco, CA, 94158
- Phone
- 41 79 934 94 49
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2023
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1971101
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 3, 2023 | New notice | $400,000 | $400,000 | 1 | Mar 20, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Thomas Hecht | Director | |
| George Scangos | Director | |
| Sung Lee | Executive Officer, Director | |
| Johanna Friedl-Naderer | Director | |
| Natascha Schill | Executive Officer, Director | |
| Vanina de Verneuil | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Apr 3, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Encentrio Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.